ReachRxResearch
Home
Research
Sign Up
Incidence of clinically diagnosed infections in children with sickle cell anaemia treated with oral hydroxyurea in Angola, DR Congo, Kenya, and Uganda: a retrospective cohort study from the REACH trial
Back to Research Hub
  1. Home
  2. Research Hub
  3. Incidence of clinically diagnosed infect…

Incidence of clinically diagnosed infections in children with sickle cell anaemia treated with oral hydroxyurea in Angola, DR Congo, Kenya, and Uganda: a retrospective cohort study from the REACH trial

The Lancet Haematology·October 7Open Access
HematologyPractice changingSickle Cell AnaemiaRetrospective Cohort StudyCytoreductive AgentPediatricHydroxyurea

Summary

View source

What was studied

Whether oral hydroxyurea (fixed-dose, dose-escalation, and maximum tolerated dose [MTD] phases) increases clinically diagnosed infection rates in children aged 1–10 years with sickle cell anaemia across four sub-Saharan African countries (Angola, DR Congo, Kenya, Uganda) in the REACH trial (2014–2016).

Key findings

Hydroxyurea did not increase infection risk; non-malarial infection rates fell significantly from screening to MTD phase (adjusted IRR 0.51, 95% CI 0.43–0.61, p<0.0001). Across 5,638 person-years, 5,493 infections occurred (97.4/100 PYO overall), with decreases seen in upper and lower respiratory tract infections, bacterial skin/nail infections, non-specific infectious syndromes, and grade ≥3 infections at MTD.

Study limitations

Open-label, single-arm design with no concurrent control group means confounding over time cannot be fully excluded. Infections were clinically diagnosed without systematic laboratory confirmation, limiting aetiological certainty. The cohort was drawn from four specific African hospital settings, which may limit generalisability to other regions or healthcare contexts.

Clinical implications

Clinicians can reassure families that hydroxyurea—even at maximum tolerated dose—does not raise the risk of serious infections in children with sickle cell anaemia; infection rates actually declined as treatment progressed.

Caveats

  • All infections were clinically diagnosed without routine microbiological confirmation, so pathogen-specific conclusions are not possible
  • Findings are from four hospital-based cohorts in sub-Saharan Africa; infection epidemiology (especially malaria) differs substantially from high-income settings, limiting direct extrapolation
  • The single-arm design means that observed declines in infection rates over time could partly reflect natural disease course, regression to the mean, or improved clinical familiarity rather than a hydroxyurea effect

Related Questions

Explore related topics

Does hydroxyurea increase infection risk in children with sickle cell disease?Hydroxyurea maximum tolerated dose safety in pediatric sickle cell anaemia in sub-Saharan AfricaREACH trial outcomes hydroxyurea sickle cell Africa

Publication Details

Year
2026
Journal
The Lancet Haematology
Sample Size
n=606
Source
View article
Keep scrolling
More content below.
Up Next